Skip to main content
C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc. — Investor Relations & Filings

Ticker · CCCC ISIN · US12529R1077 US Manufacturing
Open in API
Filings indexed 497 across all filing types
Latest filing 2026-05-15 Board/Management Inform…
Country US United States of America
Listing US CCCC

About C4 Therapeutics, Inc.

https://c4therapeutics.com/

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of a new class of small-molecule medicines through targeted protein degradation (TPD). The company's proprietary TORPEDO (Target Oriented Protein Degrader Optimizer) platform is utilized to create therapeutics that selectively destroy disease-causing proteins. C4 Therapeutics' primary focus is on developing treatments for cancer and other diseases. Its clinical pipeline includes investigational candidates such as cemsidomide (CFT7455) for hematologic malignancies, CFT8919 for solid tumors with specific genetic mutations, and CFT1946 for BRAF V600 mutant cancers.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 91% confidence The document is a Form 8-K current report filed under Item 5.02, announcing the departure and appointment of a principal accounting officer (senior management change). This fits the definition of Board/Management Information (change in senior management).
2026-05-15 English
10-Q - C4 Therapeutics, Inc. (0001662579) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-12 English
8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
Regulatory Filings Classification · 95% confidence The document is an SEC Form 8-K “Current Report,” which is a compliance/regulatory filing disclosing items 2.02 (results of operations press release) and 7.01 (a furnished corporate presentation). It is not the earnings release itself nor the investor presentation standalone; it is the Form 8-K regulatory filing. Under our taxonomy, this falls into the “Regulatory Filings” category (RNS).
2026-05-12 English
ARS - C4 Therapeutics, Inc. (0001662579) (Filer)
Annual Report FY 2025
2026-04-29 English
DEF 14A - C4 Therapeutics, Inc. (0001662579) (Filer)
Proxy Solicitation & Information Statement
2026-04-29 English
8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 10, 2026. It reports an amendment to the company's by-laws regarding exclusive forum selection for certain legal actions. The document includes a description of the by-laws amendment and references an exhibit containing the full text of the amendment. There are no financial statements or detailed financial data presented. The content focuses on a governance change (by-laws amendment) rather than financial results or management discussion. According to the filing definitions, announcements of changes in company governance or board-related matters fall under Board/Management Information (MANG). The document is not a full annual or quarterly report, nor an earnings release or audit report. It is not a regulatory filing of miscellaneous nature since it specifically announces a governance change. Therefore, the appropriate classification is MANG with high confidence.
2026-04-10 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.